C-IRLRCoya Therapeutics
Treg-enhancing biologics, Treg-derived exosomes, Treg cell therapy
modulatingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-IRLR
C-IRLRC-IRLRTreg-enhancing biologics, Treg-derived exosomes, Treg cell therapy
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Coya Therapeutics presents the belief that regulatory T cell (Treg) dysfunction is central to neurodegenerative and autoimmune diseases, and that restoring or infusing large numbers of highly functional Tregs can suppress neuroinflammation and dampen inflammation. The company frames its proprietary platform and manufacturing approach, including cryopreservation for Tregs, as a transformative way to expand dysfunctional Tregs into billions of functional cells for treatment.
SourceCoya Therapeutics states that suppressing neuroinflammation through regulatory T cell therapy is a promising treatment approach for neurodegenerative diseases. The company presents regulatory T cell dysfunction as central to the pathophysiology of both neurodegenerative and autoimmune diseases and indicates that its proprietary manufacturing process enables production of highly functional Tregs to address this mechanism.
SourceCoya Therapeutics states that enhancing the function and power of regulatory T cells (Tregs) can be developed into multiple therapeutic modalities to treat neurodegenerative, autoimmune, and metabolic diseases, and presents this Treg-centered approach as the basis of its clinical-stage biotechnology strategy.
Source